JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 48(2014) N 2 p. 297-300; DOI 10.1134/S0026893314020150 Full Text

M.M. Prokofjeva1, N.N. Orlova1,2, A.S. Gornostaeva1,2, A.A. Shulgin1,2, N.A. Nikitenko1, V.N. Senchenko1, T.D. Lebedev1, P.V. Spirin1, K. Riecken3, B. Fehse3, C. Stocking3, V.S. Prassolov1,2*

Universal Modular System for in vitro Screening of Potential Inhibitors of HIV-1 Replication

1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia
2Moscow Physico-Technical Institute, Dolgoprudnyi, Moscow Region, 141700, Russia
3University Medical Center Hamburg-Eppendorf, Research Dept. Cell & Gene Therapy, Hamburg, D-20246, Germany
4Heinrich-Pette-Institute for Experimental Virology and Immunology, Hamburg, D-20251, Germany


*prasolov@eimb.ru
Received - 2013-10-09; Accepted - 2013-10-14

A system based on recombinant lentiviral vectors has been designed for safe screening of potential anti-HIV drugs. The system can be used to evaluate the sensitivity of HIV-1 reverse transcriptase and integrase (wild-type as well as mutant forms of these enzymes detected in drug-resistant virus isolates) to different drugs and substances, as well as to screen inhibitors of other stages of the HIV-1 life cycle.

HIV, pseudo-HIV-1 particles, reverse transcriptase, nucleoside inhibitors, non-nucleoside inhibitors, integrase inhibitors, sulfated polysaccharides



JMB-FOOTER RAS-JOURNALS